Identification of Correlations Between Reaction to Biotine and Autoimmune Diseases
NCT01934764 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60
Last updated 2013-09-04
Summary
Working hypothesis and aims: Biotin is conjugated covalently to several proteins and use as a co-factor. Conjugation of biotin to non-targeted, unspecific proteins (e.g. immunoglobulins) leads to the breakage of the immune tolerance and to the formation of anti-biotin antibodies. Anti-biotin antibodies will be found in correlation with the progression and the present of autoimmune disease. In this research the correlation between immune response against biotin and the formations of autoimmune disease, will be studied:
A. Assessment of the possibility that biotin elicit immune response involved in the developmental stage of the autoimmune disease.
B. Assessment of the possibility that anti-biotin antibodies indicate the developmental stage of the autoimmune disease and therefore can serve as an disease early stage marker.
Methods: A. Patient recruitment. Gathering participant's medical record and blood samples. B. Records of clinical and biochemical measures. C. Serum of all patient will be tested for the correlation between biotin level, biotin bound to antibodies and anti-biotin antibodies to liver functions tests. D. Controlled test for repeatedly injected mice with biotinilated self-antibodies. Level of anti-biotin will be tested and their influence on the mouse. E. Determination of the correlation between biotinilated antibodies or anti-biotin antibodies to disease eruption or severance and autoimmune disease.
Expected results :Serum biotin-protein levels and Anti biotin antibodies levels are increased in patients with active autoimmune liver diseases.
Importance: The proof of connection between biotin-carrying immunoglobulins, anti biotin antibodies and autoimmune diseases will open new research direction of possible factors that cause to autoimmune disease.
Probable implications to Medicine: Identification of correlations between reaction to biotine and autoimmune diseases will enable their usage as biomarkers for autoimmune diseases, severity of the disease and personalization of treatment.
Conditions
Sponsors & Collaborators
-
Ziv Hospital
lead OTHER_GOV
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-09-30
- Primary Completion
- 2014-09-30
Countries
- Israel
Study Locations
More Related Trials
-
Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis
NCT04186871 ·Status: COMPLETED ·Phase: PHASE2
-
Vitamin B12: a Biological Marker of Systemic Disease or Infection Flare-up in Patients Treated with Tocilizumab?
NCT06654154 ·Status: RECRUITING ·Phase: NA
-
COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
NCT05000216 ·Status: TERMINATED ·Phase: PHASE2
-
Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE
NCT01702038 ·Status: WITHDRAWN ·Phase: PHASE2
-
Analysis of B Cells From Autoimmune Individuals
NCT02747277 ·Status: COMPLETED
-
Evaluating the Immune Response to COVID19 Vaccination in Immunodeficient Patients
NCT05286242 ·Status: ACTIVE_NOT_RECRUITING
-
Safety Study of CDP7657 in Patients With Systemic Lupus Erythematosus
NCT01764594 ·Status: COMPLETED ·Phase: PHASE1
-
Autoantibodies Prevalence During Checkpoint Inhibitor Treatment
NCT04220034 ·Status: COMPLETED
-
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus
NCT02535689 ·Status: COMPLETED ·Phase: PHASE1
-
The Relationship Between COVID-19 and Autoimmune Diseases, Lessons From Practice
NCT04558203 ·Status: COMPLETED
-
Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases
NCT06828042 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE Participants
NCT06625671 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD)
NCT06977724 ·Status: RECRUITING ·Phase: PHASE1
-
Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity
NCT03941184 ·Status: COMPLETED
-
A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus
NCT02725515 ·Status: COMPLETED ·Phase: PHASE2
-
Role of Antibodies in Cognitive Dysfunction in Patients With Systemic Lupus Erythematosus
NCT00042523 ·Status: COMPLETED
-
An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease
NCT06379646 ·Status: RECRUITING ·Phase: NA
-
Ro60 Expression in Macrophages in Sjogren's Disease
NCT06324968 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Evaluation of Patients With Systemic Sclerosis Without Specific or Associated Autoantibodies
NCT06412614 ·Status: NOT_YET_RECRUITING
-
Autoantibodies in Treatment with Immune Checkpoint Inhibitors (AUTENTIC)
NCT03868046 ·Status: COMPLETED
-
Study of Autoimmune Disease Complications Following Ipilimumab Treatment Among Melanoma Patients With Underlying Autoimmune Diseases
NCT02739386 ·Status: COMPLETED
-
Evaluation of the Prevalence of BP180 and BP230 Autoantibodies in the Serum of Patients With Pruritus Under Immunotherapy
NCT05689463 ·Status: RECRUITING ·Phase: NA
-
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus
NCT01262365 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Telitacicept on Transitional Regulatory B Cells in Patients With Systemic Lupus Erythematosus
NCT06137053 ·Status: RECRUITING
-
Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
NCT02446899 ·Status: COMPLETED ·Phase: PHASE3